Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 12, 2014, Pages 4481-4486

  Vita, Roberto ^a   Saraceno, Giovanna ^a   Trimarchi, Francesco ^a   Benvenga, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; LEVOTHYROXINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; THYROTROPIN; SOLUTION AND SOLUBILITY; TABLET; THYROXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; HORMONE INHIBITION; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MALE; OBSERVATIONAL STUDY; ORAL SOLUTION; PROSPECTIVE STUDY; STOMACH PH; TABLET; THYROTROPIN BLOOD LEVEL; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; INTESTINE ABSORPTION; MIDDLE AGED; SOLUTION AND SOLUBILITY;

ADULT; AGED; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PHARMACEUTICAL SOLUTIONS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TABLETS; THYROTROPIN; THYROXINE;

EID: 84916629459     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2684     Document Type: Article

References (28)

1. Bartholow M.Top 200 drugs of 2012. Pharmacy Times. http:// www.pharmacytimes.com/publications/issue/2013/July2013/Top-200-Drugs-of-2012. Accessed July 24, 2014.
2. Benvenga S, Trimarchi F. Changed presentation of Hashimoto's thyroiditis in North-Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid. 2008;18:429-441.
3. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
4. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354:1787-1795.
5. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72:105-110.
6. Benvenga S, Bartolone L, Squadrito S, Lo Giudice F, Trimarchi F. Delayed intestinal absorption of levothyroxine. Thyroid. 1995;5: 249-253.
7. Hays MT. Localization of human thyroxine absorption. Thyroid. 1991;1:241-248.
8. Colucci P, Yue CS, Ducharme M, Benvenga S. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol. 2013;9:40-47.
9. Hays MT, Nielsen KR. Human thyroxine absorption: age effects and methodological analyses. Thyroid. 1994;4:55-64.
10. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism. 1977;26:1-8.
11. Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab. 2009;94:3905-3912.
12. Benvenga S. Whenthyroid hormone replacement is ineffective? Curr Opin Endocrinol Diabetes Obes. 2013;20:467-477.
13. Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol. 2005;60:337-341.
14. Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008;18:293-301.
15. Virili C, Bassotti G, Santaguida MG, et al. Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J Clin Endocrinol Metab. 2012;97:E419-E422.
16. Asik M, Gunes F, Binnetoglu E, et al. Decrease in TSH levels after lactose restriction in Hashimoto's thyroiditis patients with lactose intolerance. Endocrine. 2014;46:279-284.
17. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11:41-50.
18. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13:345-349.
19. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267-1272.
20. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-534.
21. Colucci P, D'Angelo P, Mautone G, Scarsi C, Ducharme MP. Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther Drug Monit. 2011;33:355-361.
22. Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine. 2013;43:154-160.
23. Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62:631-636.
24. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012;22:1200-1235.
25. Donangelo I, Braunstein GD. Update on subclinical hyperthyroidism. Am Fam Physician. 2011;83:933-938.
26. Cappelli C, Pirola I, Gandossi E, Formenti A, Castellano M. Oral liquid levothyroxine treatment at breakfast: a mistake? Eur J Endocrinol. 2014;170:95-99.
27. Bernareggi A, Grata E, Pinorini MT, Conti A. Oral liquid formulation of levothyroxine is stable in breakfast beverages and may improve thyroid patient compliance. Pharmaceutics. 2013;5:621-633.
28. Pirola I, Formenti AM, Gandossi E, et al. Oral liquid L-thyroxine (L-T4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes Surg. 2013;23:1493-1496.